Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 108 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Spironolactone 100mg Clear all
Completed Not applicable Interventional Results available

Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications

NCT01406015
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Sep 1, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men

NCT01294319
View directory record Official record
Conditions
Cortisol Resistance, Negative Feedback, ACTH, Mineralcorticoid, Glucocorticoid
Interventions
Mifepristone, Placebo, Spironolactone, Combined, Dexamethasone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 80 Years · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2024 · Synced Sep 1, 2026, 10:58 AM EDT
Completed Phase 2 Interventional

Polypill Strategy for Heart Failure With Reduced Ejection Fraction

NCT04633005
View directory record Official record
Conditions
Heart Failure
Interventions
Polypill, Control Rx
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 1, 2026, 10:58 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Spironolactone Therapy In Young Women With NASH

NCT03576755
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Spironolactone 100mg, Placebo oral capsule
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 1, 2026, 10:58 AM EDT
Completed Phase 4 Interventional Results available

Antiarrhythmic Effects of Spironolactone in Patients With ICDs

NCT04495712
View directory record Official record
Conditions
Ventricular Arrhythmias
Interventions
spironolactone, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Sep 1, 2026, 10:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Fitness and Mineralocorticoid Receptor Blockade on Vascular Dysfunction in Adults With Type 1 Diabetes

NCT03174288
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Exercise, Spironolactone
Other · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Sep 1, 2026, 10:58 AM EDT
Completed Not applicable Interventional

Spironolactone to Decrease Potassium Wasting in Hypercalciurics on Thiazides Diuretics

NCT00276289
View directory record Official record
Conditions
Idiopathic Hypercalciuria, Hypokalemia Caused by Thiazide Diuretics
Interventions
Spironolactone
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 2, 2009 · Synced Sep 1, 2026, 10:58 AM EDT
Withdrawn Not applicable Interventional

Aliskiren and Renin Inhibition in Diastolic Heart Failure

NCT00773084
View directory record Official record
Conditions
Diastolic Heart Failure
Interventions
Aliskiren plus spironolactone vs. Lisinopril plus spironolactone
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
21 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Sep 1, 2026, 10:58 AM EDT
Completed Not applicable Interventional

Controlling Blood Pressure in Treatment Resistant Hypertension: A Pilot Study

NCT02167464
View directory record Official record
Conditions
Hypertension
Interventions
Renin treatment-guided Therapeutics, Referral Hypertension specialist, Aldosterone Antagonist
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Anderson, South Carolina • Beaufort, South Carolina • Florence, South Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2018 · Synced Sep 1, 2026, 10:58 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)

NCT00141778
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Placebo, Ramipril, Spironolactone
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Sep 1, 2026, 10:58 AM EDT
Completed Not applicable Interventional

Spironolactone for Reducing Proteinuria in Diabetic Nephropathy

NCT00498537
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
spironolactone
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 16, 2008 · Synced Sep 1, 2026, 10:58 AM EDT
Completed Phase 4 Interventional

Novel Treatment for Diastolic Heart Failure in Women

NCT00206232
View directory record Official record
Conditions
Heart Failure
Interventions
Spironolactone
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2013 · Synced Sep 1, 2026, 10:58 AM EDT
Completed Phase 4 Interventional Results available

Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension

NCT00353652
View directory record Official record
Conditions
Hypertension
Interventions
Study#1: chlorthalidone (CTD), titrated dose, Study #1: spironolactone (SP), titrated dose, Study# 2 chlorthalidone (CTD), fixed dose, Study# 2 spironolactone (SP), fixed dose, Study# 2 irbsesartan (IR), fixed dose
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Sep 1, 2026, 10:58 AM EDT
Withdrawn Phase 4 Interventional

High-Dose Aldactone for Treatment of Diuretic Resistant Heart Failure

NCT02429388
View directory record Official record
Conditions
Heart Failure
Interventions
Spironolactone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Sep 1, 2026, 10:58 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia

NCT02483195
View directory record Official record
Conditions
Female Androgenetic Alopecia
Interventions
5% Minoxidil, 200mg Spironolactone, 5mg Finasteride, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
60 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Sep 1, 2026, 10:58 AM EDT
Withdrawn Phase 4 Interventional

Left Ventricular Hypertrophy and Spironolactone in End Stage Renal Disease

NCT00548912
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Spironolactone
Drug
Lead sponsor
Dawnmarie DeFazio
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Sep 1, 2026, 10:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Learn How the Body Processes Spironolactone and Hydrochlorothiazide Film Coated Tablets Manufactured at Two Sites: Viatris and Neolpharma

NCT06205407
View directory record Official record
Conditions
Healthy Participants
Interventions
Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris, Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma.
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 1, 2026, 10:58 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Hypoglycemia and Autonomic Nervous System Function-B

NCT03429946
View directory record Official record
Conditions
Hypoglycemia, Healthy
Interventions
Spironolactone, Placebo, Hypoglycemic Hyperinsulinemic Clamp, Euglycemic Hyperinsulinemic Clamp
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Sep 1, 2026, 10:58 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Spironolactone Versus Amiloride as an Add on Agent in Resistant Hypertension

NCT00709137
View directory record Official record
Conditions
Hypertension
Interventions
spironolactone, amiloride
Drug
Lead sponsor
VA Salt Lake City Health Care System
Federal
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 27, 2014 · Synced Sep 1, 2026, 10:58 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation

NCT02232880
View directory record Official record
Conditions
Hypertension
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Sep 1, 2026, 10:58 AM EDT
Not listed Phase 2Phase 3 Interventional

Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease

NCT01721655
View directory record Official record
Conditions
Chronic Lung Disease, Bronchopulmonary Dysplasia
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
West Virginia University Healthcare
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Sep 1, 2026, 10:58 AM EDT
Completed Phase 2 Interventional

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 1

NCT06004830
View directory record Official record
Conditions
Alcohol Use Disorder, Hiv
Interventions
Spironolactone
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 1, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function

NCT00094302
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Heart Failure, Congestive
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Carelon Research
Other
Eligibility
50 Years and older
Enrollment
3,445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
155
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 120 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2015 · Synced Sep 1, 2026, 10:58 AM EDT
Not listed Phase 4 Interventional

Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension

NCT01468571
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Sep 1, 2026, 10:58 AM EDT